CAMBER CAPITAL MANAGEMENT LP
Q2 2022 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001444043
· CRD 298070
· SEC-registered investment adviser
$2.3B Reported Value Total
CAMBER CAPITAL MANAGEMENT LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $3,548,064,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
2 funds
· $3.6B gross asset value
Hedge Fund: $3.6B
Source: Form ADV filed 2025-04-09
Reported value
$2.3B
Quarter over quarter
-12.1%
Holdings
40
Top-10 concentration
58.9%
Key People
Form ADV owners & control persons
Stephen Rodney Dubois
MANAGING MEMBER
Brian James Foley
CHIEF OPERATING OFFICER
Sean George
CHIEF FINANCIAL OFFICER/CHIEF COMPLIANCE OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2022 13F record
Q2 2022 13F filing summary
| Period of report | June 30, 2022 |
|---|---|
| Filed | August 15, 2022 |
| Form | 13F-HR |
| Reported value | $2.3B |
| Positions | 40 |
| Change in reported value | -16.6% |
| New positions | 10 |
| Exited positions | 7 |
| Position turnover | 36.2% |
| Top-10 concentration | 58.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2025 13F
Filed Aug 14, 2025
|
23 | $1.1B |
|
Q1 2025 13F
Filed May 15, 2025
|
28 | $2.8B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
36 | $4.3B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
32 | $3.1B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
35 | $3.6B |
|
Q1 2024 13F
Filed May 15, 2024
|
34 | $4.1B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
36 | $3.9B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
39 | $3.0B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
38 | $3.1B |
|
Q1 2023 13F
Filed May 15, 2023
|
40 | $3.3B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
38 | $2.9B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
42 | $3.3B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
40 | $2.3B |
|
Q1 2022 13F
Filed May 16, 2022
|
37 | $2.8B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
36 | $2.9B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
34 | $3.2B |
|
Q2 2021 13F
Filed Aug 16, 2021
|
30 | $3.0B |
|
Q1 2021 13F
Filed May 17, 2021
|
31 | $2.9B |
|
Q4 2020 13F
Filed Feb 16, 2021
|
28 | $2.8B |
|
Q3 2020 13F
Filed Nov 16, 2020
|
35 | $1.9B |
29 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | VTRS VIATRIS INC | $240.8M | 10.45% |
| 2 | SNY SANOFI | $200.1M | 8.68% |
| 3 | ZBH ZIMMER BIOMET HOLDINGS INC | $141.8M | 6.15% |
| 4 | SRPT SAREPTA THERAPEUTICS INC | $138.7M | 6.02% |
| 5 | BMRN BIOMARIN PHARMACEUTICAL INC | $124.3M | 5.39% |
| 6 | PRGO PERRIGO CO PLC | $111.6M | 4.84% |
| 7 | WBA WALGREENS BOOTS ALLIANCE INC | $107.1M | 4.65% |
| 8 | IONS IONIS PHARMACEUTICALS INC | $100.0M | 4.34% |
| 9 | PTCT PTC THERAPEUTICS INC | $98.1M | 4.26% |
| 10 | SEM SELECT MED HLDGS CORP | $94.5M | 4.1% |
| 11 | INCY INCYTE CORP | $91.2M | 3.96% |
| 12 | MYGN MYRIAD GENETICS INC | $90.9M | 3.94% |
| 13 | THC TENET HEALTHCARE CORP | $86.7M | 3.76% |
| 14 | UHS UNIVERSAL HLTH SVCS INC | $75.0M | 3.26% |
| 15 | BKD BROOKDALE SR LIVING INC | $72.6M | 3.15% |
| 16 | CHNG CHANGE HEALTHCARE INC | $53.6M | 2.33% |
| 17 | RETA REATA PHARMACEUTICALS INC | $45.6M | 1.98% |
| 18 | XRAY DENTSPLY SIRONA INC | $44.7M | 1.94% |
| 19 | MRTX MIRATI THERAPEUTICS INC | $43.6M | 1.89% |
| 20 | EXEL EXELIXIS INC | $34.4M | 1.49% |
Values as reported on the Q2 2022 Form 13F. Every position is in the holdings table below.